Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc. (DE:19X)
:19X
19X Stock Chart & Stats
Day’s Range― - ―
52-Week Range€59.56 - €135.55
Previous CloseN/A
Volume0.00
Average Volume (3M)28.00
Market Cap
€4.87B
Enterprise Value€3.99B
Total Cash (Recent Filing)-$2.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.07
Next Earnings
May 05, 2025EPS Estimate
-1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.55
Shares Outstanding49,219,310
10 Day Avg. Volume2
30 Day Avg. Volume28
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.34
Enterprise Value/Ebitda-14.55
Forecast
1Y Price Target
€154.98Price Target Upside58.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
---
Axsome Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Market PotentialVisible Alpha consensus sales for Auvelity are expected to grow to $1B by 2027.
Product PipelineAxsome's positive Phase III SYMPHONY trial of AXS-12 (reboxetine) in type NT1 will be presented as part of the clinical trial’s plenary session at the AAN meeting.
Sales GrowthAuvelity achieved 26K new patient starts in 4Q, bringing the total number of new patient starts since launch to 165K.
Bears Say
Clinical Study ConcernsDr. Maski would like to see more concrete improvements in excessive daytime sleepiness or mood benefits to use as monotherapy.
Investor FocusInvestor focus is primarily on Auvelity in depression and Alzheimer’s disease agitation, potentially overshadowing AXS-12.
Weekly Sales PerformanceAuvelity had an off week, with reported w/w TRx/NRx growth of -5%/-6%.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.41% Insiders
19.33%
Mutual Funds
35.50% Other Institutional Investors
30.90% Public Companies and
Individual Investors
19X FAQ
What was Axsome Therapeutics Inc.’s price range in the past 12 months?
Axsome Therapeutics Inc. lowest stock price was €59.56 and its highest was €135.55 in the past 12 months.
What is Axsome Therapeutics Inc.’s market cap?
Axsome Therapeutics Inc.’s market cap is €4.87B.
When is Axsome Therapeutics Inc.’s upcoming earnings report date?
Axsome Therapeutics Inc.’s upcoming earnings report date is May 05, 2025 which is today.
How were Axsome Therapeutics Inc.’s earnings last quarter?
Axsome Therapeutics Inc. released its earnings results on Feb 18, 2025. The company reported -€1.363 earnings per share for the quarter, missing the consensus estimate of -€0.886 by -€0.477.
Is Axsome Therapeutics Inc. overvalued?
According to Wall Street analysts Axsome Therapeutics Inc.’s price is currently Undervalued.
Does Axsome Therapeutics Inc. pay dividends?
Axsome Therapeutics Inc. does not currently pay dividends.
What is Axsome Therapeutics Inc.’s EPS estimate?
Axsome Therapeutics Inc.’s EPS estimate is -1.19.
How many shares outstanding does Axsome Therapeutics Inc. have?
Axsome Therapeutics Inc. has 49,219,310 shares outstanding.
What happened to Axsome Therapeutics Inc.’s price movement after its last earnings report?
Axsome Therapeutics Inc. reported an EPS of -€1.363 in its last earnings report, missing expectations of -€0.886. Following the earnings report the stock price went down -6.349%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc.?
Currently, no hedge funds are holding shares in DE:19X
---
Axsome Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€154.98 (58.02% Upside)
€154.98 (58.02% Upside)
Blogger Sentiment
Bullish
DE:19X Sentiment 70%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.24%
12-Months-Change
Fundamentals
Return on Equity
-231.63%
Trailing 12-Months
Asset Growth
-3.36%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
---
19X Company Deck
---
19X Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Axsome Therapeutics showed strong revenue growth and significant progress in its product pipeline, including new product approvals. However, the company continued to face high net losses and operating expenses, along with challenges in market access and pricing pressures. The overall sentiment of the call is optimistic about future growth, yet tempered by these financial challenges.Read More>---
19X Stock 12 Month Forecast
Average Price Target
€154.98
▲(58.02% Upside)
Technical Analysis
Cytokinetics
―
Sarepta Therapeutics
―
Blueprint Medicines
―
Verona Pharma
―
Krystal Biotech
―
---